Syngene International Ltd reported a 4% sequential and 2% year-on-year growth in Q2 FY26 revenue to Rs. 911 Cr, while first half revenue increased by 6%. The company announced winning its first contract for a global phase III clinical trial from a U.S.-based biotech firm.